Lexeo Therapeutics Management
Management criteria checks 1/4
Lexeo Therapeutics' CEO is R. Townsend, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is $1.74M, comprised of 29.2% salary and 70.8% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth $497.83K. The average tenure of the management team and the board of directors is 1.8 years and 2 years respectively.
Key information
R. Townsend
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 29.2% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$87m |
| Jun 30 2024 | n/a | n/a | -US$77m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$2m | US$508k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$705k | US$465k | -US$59m |
| Dec 31 2021 | US$3m | US$411k | -US$51m |
Compensation vs Market: R.'s total compensation ($USD1.74M) is about average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
CEO
R. Townsend (43 yo)
4.8yrs
Tenure
US$1,737,218
Compensation
Mr. R. Nolan Townsend is Director of Arbor Biotechnologies, Inc. from November 2023. He is Chief Executive Officer & Director of Lexeo Therapeutics, Inc since January 2020 Before joining Lexeo, Mr. Townsen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$1.74m | 0.23% $ 497.8k | |
| Chief Medical Officer & Head of Research | less than a year | US$3.04m | 0% $ 0 | |
| Chief Business & Legal Officer | 2.7yrs | US$1.30m | 0% $ 0 | |
| Co-Founder | no data | no data | 4.04% $ 8.7m | |
| Vice President of Finance | less than a year | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Chief Development Officer | 1.8yrs | no data | 0.050% $ 107.6k | |
| VP & Corporate Controller | 2.8yrs | no data | no data |
1.8yrs
Average Tenure
49.5yo
Average Age
Experienced Management: LXEO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$1.74m | 0.23% $ 497.8k | |
| Co-Founder | 2yrs | no data | 4.04% $ 8.7m | |
| Independent Director | 2.8yrs | US$7.38k | no data | |
| Independent Director | 4yrs | US$10.50k | no data | |
| Independent Director | 3yrs | US$406.61k | 0.047% $ 101.1k | |
| Independent Chairman of the Board | 3.8yrs | US$200.15k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data |
2.0yrs
Average Tenure
65yo
Average Age
Experienced Board: LXEO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.